Pfizer Inc
PFE: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| hQ | LOCK|KxnGk | LOCK|@>qQB$@ |
Pfizer: 2025 Guidance Largely Reassuring on Covid Stability and Cost-Saving Execution
Pfizer reaffirmed its 2024 financial outlook and provided 2025 guidance implying 0%-5% top-line growth and 10%-18% non-GAAP earnings per share growth, using the midpoint of 2024 guidance excluding nonrecurring items.
